|Bid||128.74 x 800|
|Ask||128.75 x 900|
|Day's range||128.16 - 129.45|
|52-week range||121.00 - 148.99|
|Beta (3Y monthly)||0.76|
|PE ratio (TTM)||21.40|
|Earnings date||15 Oct 2019|
|Forward dividend & yield||3.80 (2.95%)|
|1y target est||149.28|
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (JNJ). The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $417 million award to one California plaintiff in August 2017 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018.
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Investors worried about dwindling sales of key drugs and mounting litigation expenses have at least five reasons to stay calm.
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
Pharmaceutical companies are facing increasing scrutiny for their alleged roles in the opioid crisis. Its next target? Johnson & Johnson (JNJ).
U.S. stocks were mixed Tuesday afternoon as investors digested a wave of signals from officials over U.S.-China trade relations and monetary policy, along with an influx of corporate earnings results and economic data.
(Bloomberg) -- Johnson & Johnson raised its revenue guidance for the year, as strong sales in its pharmaceutical unit helped cushion a decline in the consumer and medical technology businesses.Second-quarter adjusted earnings were $2.58 a share, topping the $2.45 average of analysts’ estimates. To read more details on the results, click here.Key InsightsThe company’s full revenue is actually down from a year prior. Part of that can be attributed to the company’s divestiture of its medical sterilization business, ASP, which it sold to Fortive Corp. earlier this year. The company was also hit badly by foreign exchange rates. Almost half of J&J’s sales come from outside the U.S., and its fastest-growing segment -- overseas pharmaceuticals -- had its growth cut nearly in half because of currency fluctuations.J&J’s drug business is the largest of the company’s three main segments and accounts for more than half of all revenue. Its cancer drugs, including Darzalex and Imbruvica, drove growth in the quarter and were up 9.8% from a year prior.Market ReactionThe shares were down 1% to $133.41 at 9:43 a.m. in New York. The stock is up 4.4% this year to date as of Monday’s close, trailing the broader market.(Corrects spelling of cancer drug Darzalex in “Key Insights” section.)To contact the reporter on this story: Riley Griffin in New York at firstname.lastname@example.orgTo contact the editor responsible for this story: Drew Armstrong at email@example.comFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Johnson & Johnson vowed to defend itself against lawsuits alleging the company fueled the opioid crisis and that its namesake talc-based baby powder caused ovarian cancer and mesothelioma.